Rodman & Renshaw
http://www.rodmanandrenshaw.com/Rodman & Renshaw is an investment bank. The firm provides investment banking services to companies that have significant recurring capital needs along with research, sales, and trading services to institutional investors. The firm focuses on the biotechnology sector and since 2003 has been a leading investment bank to the sector. The firm is also a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
View Older Stories
-
Rodman & Renshaw Starts Ascentage Pharma Group (AAPG) at Buy
-
Rodman & Renshaw Starts Biomea Fusion Inc. (BMEA) at Buy
-
Rodman & Renshaw Starts BioAtla Inc. (BCAB) at Buy
-
Rodman & Renshaw Starts Jasper Therapeutics (JSPR) at Buy
-
Scilex raises $20.3 million through warrant exercise
-
Scilex raises $20.3 million through warrant exercise agreement
-
Fitell secures $50 million convertible note financing for robotics venture
-
MIRA Pharmaceuticals sells 1.75M shares at 66% premium
-
Bluejay Diagnostics closes $4.5 million private placement
-
Bluejay Diagnostics raises $4.5 million in private placement
-
Fitell launches $100M Solana treasury strategy with DeFi focus
-
Actelis Networks raises $1.6 million through warrant exercise
-
Banzai International (BNZI) Secures $11M in Debt Financing
-
Kairos Pharma (KAPA) Issues Letter to Stockholders
-
Rodman & Renshaw Reiterates Buy Rating on CorMedix (CRMD), PT $20, 'weakness today is likely overdone'
-
Rodman & Renshaw Reiterates Sell Rating on Cassava Sciences (SAVA), PT $2
-
Trevi Therapeutics (TRVI) PT Raised to $20 at Rodman & Renshaw
-
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
-
Rodman & Renshaw Reiterates Buy Rating on Adial Pharmaceuticals Inc (ADIL)
-
BioXcel Therapeutics (BTAI) announces direct offering of $14 million
-
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
Rodman & Renshaw Starts Telomir Pharma (TELO) at Buy
-
Fitell Corporation (FTEL) Announces Updated Registered Direct Offering for up to $10.0 Million
-
Fitell Corporation (FTEL) Announces $10.0 Million Registered Direct Offering
-
GH Research PLC (GHRS) PT Raised to $42 at Rodman & Renshaw
-
Rodman & Renshaw Starts Cardiol Therapeutics (CRDL) at Buy
-
Rodman & Renshaw Starts Indivior (INDV) at Buy
-
Rodman & Renshaw Starts Rein Therapeutics (RNTX) at Buy
-
Rodman & Renshaw Starts PolyPid Ltd. (PYPD) at Buy
-
Rodman & Renshaw Starts Talphera (TLPH) at Buy
-
Rodman & Renshaw Starts INmune Bio Inc. (INMB) at Buy
-
Compass Pathways (CMPS) PT Lowered to $9 at Rodman & Renshaw
-
Kairos Pharma (KAPA) Provides Business Update and Outlook into 2025
-
Rodman & Renshaw Starts Atara Biotherapeutics (ATRA) at Buy
-
Rodman & Renshaw Starts TuHURA Biosciences (HURA) at Buy
-
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
-
Rodman & Renshaw Starts FibroBiologics (FBLG) at Buy
-
Rodman & Renshaw Starts Tharimmune, Inc. (THAR) at Buy
-
Rodman & Renshaw Downgrades Cassava Sciences (SAVA) to Sell, PT $20 (from $107)
-
Forte Biosciences (FBRX) Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
-
Rodman & Renshaw Starts Rockwell Medical Technologies (RMTI) at Buy
-
Rodman & Renshaw Starts Eupraxia Pharmaceuticals (EPRX) at Buy
-
Rodman & Renshaw Starts Achieve Life Sciences (ACHV) at Buy
-
Rodman & Renshaw Starts Adial Pharmaceuticals Inc (ADIL) at Buy
-
Rodman & Renshaw Starts Omeros Corp. (OMER) at Buy
-
Rodman and Renshaw Starts Bicara Therapeutics Inc (BCAX) at Buy
-
Rodman & Renshaw Starts Quince Therapeutics Inc. (QNCX) at Buy
-
Monopar Therapeutics (MNPR) Prices $19.2M Share Offering at $16.25/sh
-
Monopar Therapeutics (MNPR) Announces Proposed Share Offering

